Across the oncology pipeline worldwide, 16 percent of clinical drug trials in 2023 were for advanced solid tumors and six percent of trials were for breast cancer. This statistic shows the share of clinical trials in the oncology pipeline worldwide in 2023, by leading indication.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
EFPIA, & IQVIA. (December 9, 2024). Leading five indications across clinical trials in the oncology pipeline worldwide in 2023 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 26, 2026, from /statistics/1249168/oncology-pipeline-by-key-indication-worldwide/
EFPIA, und IQVIA. "Leading five indications across clinical trials in the oncology pipeline worldwide in 2023." Chart. December 9, 2024. ÌÇÐÄÆƽâ°æ. Accessed July 26, 2026. /statistics/1249168/oncology-pipeline-by-key-indication-worldwide/
EFPIA, IQVIA. (2024). Leading five indications across clinical trials in the oncology pipeline worldwide in 2023. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 26, 2026. /statistics/1249168/oncology-pipeline-by-key-indication-worldwide/
EFPIA, and IQVIA. "Leading Five Indications across Clinical Trials in The Oncology Pipeline Worldwide in 2023." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 9 Dec 2024, /statistics/1249168/oncology-pipeline-by-key-indication-worldwide/
EFPIA & IQVIA, Leading five indications across clinical trials in the oncology pipeline worldwide in 2023 ÌÇÐÄÆƽâ°æ, /statistics/1249168/oncology-pipeline-by-key-indication-worldwide/ (last visited July 26, 2026)
Leading five indications across clinical trials in the oncology pipeline worldwide in 2023 [Graph], EFPIA, & IQVIA, December 9, 2024. [Online]. Available: /statistics/1249168/oncology-pipeline-by-key-indication-worldwide/
